1. Hoedemaekers Y.M., Caliskan K., Michels M., et al. The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular non-compaction cardiomyopathy. Circulation Cardiovascular genetics. 2010;3(3):232-9. DOI:10.1161/CIRCGENETICS.109.903898.
2. Caliskan K., Michels M., Geleijnse M.L., et al. Frequency of Asymptomatic Disease Among Family Members With Non-compaction Cardiomyopathy. The American Journal of Cardiology. 2012;110(10):1512-7. DOI:10.1016/j.amjcard.2012.07.009.
3. Мясников Р.П., Щербакова Н.В., Куликова О.В. и др. Мутация гена DES в семье пробанда с миофибриллярной миопатией и развитием некомпактной кардиомиопатии, приведшей к трансплантации сердца. Российский Кардиологический Журнал. 2017;10(150):9-16. DOI:10.15829/1560-4071-2017-10-9-16.
4. Finsterer J., Stollberger C. Primary prophylactic anticoagulation is mandatory if non-compaction is associated with atrial fibrillation or heart failure. International Journal of Cardiology. 2015;184(1):268-69. DOI:10.1016/j.ijcard.2015.02.041.
5. Jacquier A., Thuny F., Jop B., et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. 2010;31(9):1098-104. DOI:10.1093/eurheartj/ehp595.
6. Petersen S.E., Selvanayagam J.B., Wiesmann F., et al. Left Ventricular Non-Compaction. Journal of the American College of Cardiology. 2005;46(1):101-5. DOI:10.1016/j.jacc.2005.03.045.
7. Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. DOI:10.1038/gim.2015.30.
8. Kayvanpour E., Sedaghat-Hamedani F., Gi W.T., et al. Clinical and genetic insights into non-compaction: a meta-analysis and systematic review on 7598 individuals. Clin Res Cardiol. 2019;108(11):1297-308. DOI:10.1007/s00392-019-01465-3.
9. Мясников Р.П., Благова О.В., Куликова О.В. и др. Особенности манифестации некомпактной кардиомиопатии. Кардиоваскулярная Терапияи Профилактика. 2015;14(5):78-82. DOI:10.15829/1728-8800-2015-5-78-82.
10. Li S., Zhang C., Liu N., et al. Genotype-positive status is associated with poor prognoses in patients with left ventricular non-compaction cardiomyopathy. Journal of the American Heart Association. 2018;7(20). DOI:10.1161/JAHA.118.009910.
11. van Waning J.I., Caliskan K., Hoedemaekers Y.M., et al. Genetics, Clinical Features, and Long-Term Outcome of Non-compaction Cardiomyopathy. Journal of the American College of Cardiology. 2018;71(7):711-22. DOI:10.1016/j.jacc.2017.12.019.
12. Sedaghat-Hamedani F., Haas J., Zhu F., et al. Clinical genetics and outcome of left ventricular noncompaction cardiomyopathy. Eur Heart J. 2017;38(46):3449-60. DOI:10.1093/eurheartj/ehx545.
13. Masci P.G., Barison A., Aquaro G.D., et al. Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. International journal of cardiology. 2012;157(1):43-7. DOI:10.1016/j.ijcard.2010.11.005.
14. Gulati A., Jabbour A., Ismail T.F., et al. Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy. JAMA. 2013;309(9):896. DOI:10.1001/jama.2013.1363.
15. Assomull R.G., Prasad S.K, Lyne J., et al. Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. Journal of the American College of Cardiology. 2006;48(10):1977-985. DOI:10.1016/j.jacc.2006.07.049.
16. Amzulescu M.S., Rousseau M.F., Ahn S.A., et al. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy. JACC: Cardiovascular Imaging. 2015;8(8):934-46. DOI:10.1016/j.jcmg.2015.04.015.
17. Andreini D., Pontone G., Bogaert J., et al. Long-Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle Non-compaction. Journal of the American College of Cardiology. 2016;68(20):2166-81. DOI:10.1016/j.jacc.2016.08.053.
18. Mazurkiewicz I., Petryka J., Spiewak M., et al. Clinical and prognostic relevancy of left ventricular trabeculation assessed by cardiac magnetic resonance in patients with dilated cardiomyopathy. Kar-diol Pol. 2017;75(8):794-803. DOI:10.5603/KP.a2017.0097.
19. Ivanov A., Dabiesingh D.S., Bhumireddy G.P., et al. Prevalence and Prognostic Significance of Left Ventricular Non-compaction in Patients Referred for Cardiac Magnetic Resonance Imaging. Circ Car-diovasc Imaging. 2017;10(9). pii:e006174. DOI:10.1161/CIRCIMAGING.117.006174.
20. Grigoratos C., Barison A., Ivanov A., et al. Meta-Analysis of the Prognostic Role of Late Gadolinium Enhancement and Global Systolic Impairment in Left Ventricular Non-compaction. JACC Cardiovasc Imaging. 2019;12(11 Pt 1):2141-2151. DOI:10.1016/j.jcmg.2018.12.029.
21. Luijkx T., Cramer M.J., Zaidi A., et al. Ethnic differences in ventricular hypertrabeculation on cardiac MRI in elite football players. Netherlands Heart Journal. 2012;20(10):389-95. DOI:10.1007/s12471-012-0305-7.
22. Caselli S., Ferreira D., Kanawati E., et al. Prominent left ventricular trabeculations in competitive athletes: A proposal for risk stratification and management. International Journal of Cardiology. 2016;223:590-5. DOI:10.1016/j.ijcard.2016.08.272.
23. Gati S., Papadakis M., Papamichael N.D., et al. Reversible De Novo Left Ventricular Trabeculations in Pregnant Women. Circulation. 2014;130(6):475-83. DOI:10.1161/CIRCULATION-AHA.114.008554.